Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8441421 | European Journal of Cancer | 2016 | 7 Pages |
Abstract
In this paper, an overview of current literature on MYC function and MYC+ lymphoma patient outcome is presented. Furthermore, we present 26 patients from our tertiary referral centre who were diagnosed with MYC+ lymphoma between 2009 and 2014. In our patient series, we confirm the dismal prognosis of MYC+ lymphoma patients. Intensification of classical chemotherapy does not lead to better overall survival, justifying new treatment modalities. First line therapy should be more specifically targeted against MYC and the genes and proteins that are deregulated by MYC. To this end, the first clinical trial in which MYC+ patients will be offered targeted treatment has recently been launched.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
A.V. de Jonge, T.J.A. Roosma, I. Houtenbos, W.L.E. Vasmel, K. van de Hem, J.P. de Boer, T. van Maanen, G. Lindauer-van der Werf, A. Beeker, G.J. Timmers, C.G. Schaar, M. Soesan, P.J. Poddighe, D. de Jong, M.E.D. Chamuleau,